Talk:Copanlisib

This is the talk page for discussing improvements to the Copanlisib article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Copanlisib.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

The following Wikipedia contributor may be personally or professionally connected to the subject of this article. Relevant policies and guidelines may include conflict of interest, autobiography, and neutral point of view.

Wowbagger2 (talk · contribs) This user has contributed to the article. (Works for Bayer per this disclosure)

Individuals with a conflict of interest, particularly those representing the subject of the article, are strongly advised not to directly edit the article. See Wikipedia:Conflict of interest. You may request corrections or suggest content here on the Talk page for independent editors to review, or contact us if the issue is urgent.

Todos in the drug box

I had found two topics for clarification by appropriate and interested experts: a) the "| licence_US = " did not lead to the correct drugs@fda page, neither for Aliqopa, nor ALIQOPA nor copanlisib. b) the SMILES I copied from the old chembox. However, looking at the drugs chembl page, I found a differently looking SMILES entry.

  Is this free-base vs. salt related? Which one to use?

Wowbagger2 (talk) 14:19, 15 December 2017 (UTC)[reply]

As of 2019, Aliqopa is not APPROVED by FDA but it is CONDITIONALLY APPROVED

It has not yet demonstrated it's primary endpoint, but phase 2 analyses of efficacy endpoints were highly promising. The US FDA approval pipeline is starting to conditionally approve some drugs, with the condition being they have to go demonstrate the primary endpoints. This is subtle. But a conditionally approved drug may be removed from the market. — Preceding unsigned comment added by 76.191.127.162 (talk) 15:18, 7 October 2019 (UTC)[reply]

Unclear wording

"Copanlisib has been shown to have an effect against survival and spread of cancerous B-cells."

This sounds either like Copansilib is an effective drug against cancerous B-cell or Copansilib is a dangerous drug that may actually help cancerous B-cell and lower the chance of survival. — Preceding unsigned comment added by Akangka (talk • contribs) 01:58, 6 January 2020 (UTC)[reply]

USPI wording: "Copanlisib has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines." 2003:E2:4F38:5B00:3DA4:12F9:6CF4:B62D (talk)